The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial

European Journal of Internal Medicine

Volumn 23, Issue 3, 2012, Pages 261-266

  Lunder, Mojca ^a   Janić, Miodrag ^a   Jug, Borut ^a   Šabovič, Mišo ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Arterial ageing; Arterial stiffness; Endothelial dysfunction; Fluvastatin; Prevention; Valsartan

Indexed keywords

C REACTIVE PROTEIN; FLUINDOSTATIN; PLACEBO; VALSARTAN;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; HUMAN; LOW DRUG DOSE; MALE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CAROTID ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIDDLE AGED; PULSATILE FLOW; TETRAZOLES; VALINE; VASCULAR STIFFNESS;

EID: 84858750355     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.11.011     Document Type: Article

References (24)

1. P.M. Nilsson, P. Boutouyrie, and S. Laurent Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention Hypertension 54 2009 3 10
2. S. Pepe, and E.G. Lakatta Aging hearts and vessels: masters of adaptation and survival Cardiovasc Res 66 2005 190 193 (Pubitemid 40471033)
3. S. Carerj, C. Nipote, C. Zimbalatti, C. Zito, L. Sutera Sardo, and G. Dattilo Normal vascular aging evaluated by a new tool: e-tracking Eur J Echocardiogr 2006 49 [suppl: S]
4. L. Lind Impact of ageing on the measurement of endothelium-dependent vasodilation Pharmacol Rep 58 Suppl 2006 41 46
5. H.A. Hadi, C.S. Carr, and J. Al Suwaidi Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome Vasc Health Risk Manag 1 2005 183 198
6. A. Wykretowicz, P. Gerstenberger, P. Guzik, A. Milewska, T. Krauze, and K. Adamska Arterial stiffness in relation to subclinical atherosclerosis Eur J Clin Invest 39 2009 11 16
7. S. Laurent, J. Cockcroft, L. Van Bortel, P. Boutouyrie, C. Giannattasio, and D. Hayoz Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 27 2006 2588 2605 (Pubitemid 44627304)
8. H. Tomiyama, and A. Yamashina Non-invasive vascular function tests: their pathophysiological background and clinical application Circ J 74 2010 24 33
9. A. Blum, and R. Shamburek The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis Atherosclerosis 203 2009 325 330
10. P. Jankowski, M.E. Safar, and A. Benetos Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system Curr Pharm Des 15 2009 571 584
11. M. Sugiyama, M. Ohashi, H. Takase, K. Sato, R. Ueda, and Y. Dohi Effects of atorvastatin on inflammation and oxidative stress Heart Vessels 20 2005 133 136 (Pubitemid 41031009)
12. L. Castilla Guerra, M. del Carmen Fernandez Moreno, J.M. Lopez Chozas, and M.D. Jimenez Hernandez Statins in stroke prevention: what an internist should know Eur J Intern Med 19 2008 8 14
13. O. Hussein, J. Shneider, M. Rosenblat, and M. Aviram Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients J Cardiovasc Pharmacol 40 2002 28 34 (Pubitemid 34705528)
14. M. Horiuchi, T.X. Cui, Z. Li, J.M. Li, H. Nakagami, and M. Iwai Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation Circulation 107 2003 106 112 (Pubitemid 36070941)
15. L. Liu, S.P. Zhao, H.N. Zhou, Q.Z. Li, and J.X. Li Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension J Cardiovasc Pharmacol 50 2007 50 55 (Pubitemid 47220446)
16. M. Lunder, M. Janic, S. Habjan, and M. Sabovic Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males a pilot study Atherosclerosis 215 2011 446 451
17. M. Lunder, M. Janic, and M. Sabovic Reduction of age-associated arterial wall changes by low-dose valsartan Eur J Cardiovasc Prev Rehabil 2011 10.1177/1741826711423104
18. M.C. Corretti, T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, and M.A. Creager Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2002 257 265 (Pubitemid 34084631)
19. D.S. Celermajer, K.E. Sorensen, V.M. Gooch, D.J. Spiegelhalter, O.I. Miller, and I.D. Sullivan Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 340 1992 1111 1115
20. K.K. Koh, S.H. Han, P.C. Oh, E.K. Shin, and M.J. Quon Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction Atherosclerosis 209 2010 307 313
21. M. Yoshikawa, K. Nakamura, S. Nagase, S. Sakuragi, K.F. Kusano, and H. Matsubara Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis J Cardiovasc Pharmacol 53 2009 179 186
22. P.L. van Haelst, J.J. van Doormaal, J.F. May, R.O. Gans, H.J. Crijns, and J.W. Tervaert Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein Eur J Intern Med 12 2001 503 509 (Pubitemid 33070348)
23. C. Skogastierna, L. Luksha, K. Kublickiene, E. Eliasson, A. Rane, and L. Ekstrom Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide Heart Vessels 2011 10.1007/s00380-010-0097-x
24. P.M. Ridker, J.G. MacFadyen, F.A. Fonseca, J. Genest, A.M. Gotto, and J.J. Kastelein Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes 2 2009 616 623